Search results for: Cervical Cancer
Filter search results
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…2025. “Positive recommendations” refers to any decision that enables patient access, including optimised and Cancer Drugs Fund decisions. Policy shifts: UK, EU, and US United Kingdom Five years ago, the…
Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds
31 March 2026
…this, the researchers assumed the ratio of expenditure to burden for ASCVD is roughly the same as for all other noncommunicable diseases (NCDs), like diabetes, cancers, and respiratory diseases. They note that…
Real Option Value and Path Dependence in Oncology Innovation
1 April 2014
Based on an OHE Lunchtime Seminar, this publication addresses a persistent issue: how to adequately reward innovation through the pricing of new medicines given the limitations of the information available…
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
1 December 2016
Published paper using MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL….
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the expected additional benefits from…